Welcome to our dedicated page for AZZ news (Ticker: $AZZ), a resource for investors and traders seeking the latest updates and insights on AZZ stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect AZZ's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of AZZ's position in the market.
AZZ Inc. announced its participation in the Oppenheimer 19th Annual Industrial Growth Conference and B. Riley Financial 24th Annual Institutional Investor Conference in May 2024. David Nark, Senior Vice President, Marketing, Communications, and Investor Relations will represent the company. The Oppenheimer conference will be held from May 6-9, 2024, while the B. Riley conference will take place on May 22-23, 2024.
AZZ Inc. announced the closing of a public offering of 4.6 million shares of common stock, generating gross proceeds of $322 million. The offering included the full exercise of the underwriters' option to buy an additional 600,000 shares. The net proceeds will be used to redeem the Company's 6.0% Series A Convertible Preferred Stock.
